1.
探讨淋巴结微转移预后作用的主要临床研究
Major clinical studies of the prognostic value of lymph node micrometastasis
| Study (Year) | Number of patients | Method/Marker | Frequency of positivity in | Prognostic relevance | |
| Histology negative nodes | Patients with pN0 disease | ||||
| MASA: mutant allele specific amplification; NA: not available; TFS: tumor-free survival; OS: overall survival; DFS: disease free survival. | |||||
| Chen et al (1993)[38] | 65 | IHC/Polyclonal (antikeratin) | 102/588 (17.0%) | 38/60 (63.0%) | Trend toward shorter survival time |
| Kubuschok et al (1999)[15] | 125 | IHC/Ber-Ep4 | 35/565 (6.2%) | 11/70 (16.0%) | Worse OS (P < 0.000, 1); Worse DFS (P < 0.000, 1) |
| Hashimoto et al (2000)[39] | 31 | MASA/P53, K-ras mutation | 47/170 (28.0%) | 6/22 (27.0%) | Worse disease-specific survival |
| Osaki et al (2002)[27] | 115 | IHC/AE1, AE3 | 42/2, 432 (1.7%) | 32/115 (28.0%) | Worse OS; Higher RR (P=0.01) |
| Tezel et al (2006)[40] | 21 | IHC/Ber-Ep4, AE1, E3 | NA | NA | Reduced DFS (P=0.002) |
| Rena et al (2007)[19] | 87 | IHC/AE1, AE3 | 19/694 (2.7%) | 14/87 (16.0%) | No significance |
| Li et al (2008)[41] | 89 | RT-PCR/MUC1 mRNA | 36/402 (9.0%) | 21/89 (23.6%) | Worse OS (P < 0.05) |
| Ouyang et al (2008) | 78 | IHC/AE1, AE3 | NA | 21/78 (26.9%) | Worse OS (P=0.008) |
| Yamashita et al (2010)[42] | 117 | IHC/cytokeratin | NA | 34/117 (29.1%) | Poor survival (P < 0.001) |
| Rusch et al (2011)[18] | 1047 | IHC/cytokeratin | NA | 130/580 (22.4%) | Worse DFS (P=0.009); Worse OS (P < 0.007) |
| Li et al (2013)[43] | 44 | RT-PCR/surviving and livin mRNA | 79/286 (27.6%) | 15/44 (34.1%) | Worse TFS (P=0.007); Worse OS (P=0.01) |
| Dai et al (2013)[44] | 49 | RT-PCR/FHIT and CDKN2A transcript deletion | FHIT: 39/176 (22.0%); CDKN2A: 22/116 (19.0%) | 16/49 (32.7%) | Reduced DFS (P=0.001); Reduced OS (P=0.002) |